Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background

Abstract

Peer reviewed

J.G. Robinson, M. Farnier, J.J. Kastelein, E.M. Roth, M.R. Taskinen, H.M. Colhoun, A. Brunet, A.T. DiCioccio, G. Lecorps, R. Pordy, …

Atherosclerosis, Vol.252, pp.e231-e231

09/2016

DOI: 10.1016/j.atherosclerosis.2016.07.219

View Online

Title: Subtitle: Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background
Creators: J.G. Robinson - University of Iowa
M. Farnier - Point Médical, Lipid Clinic, Dijon, France
J.J. Kastelein - Academic Medical Center
E.M. Roth - Sterling Research Group
M.R. Taskinen - University of Helsinki
H.M. Colhoun - University of Iowa
A. Brunet - Sanofi
A.T. DiCioccio - Regeneron
G. Lecorps - Sanofi
R. Pordy - Regeneron
M.T. Baccara-Dinet - Sanofi
C.P. Cannon - Baim Institute for Clinical Research
Resource Type: Abstract
Publication Details: Atherosclerosis, Vol.252, pp.e231-e231
Publisher: Elsevier B.V
DOI: 10.1016/j.atherosclerosis.2016.07.219
ISSN: 0021-9150
eISSN: 1879-1484
Language: English
Date published: 09/2016
Academic Unit: Epidemiology; Fraternal Order of Eagles Diabetes Research Center
Record Identifier: 9984364540202771

3 Record Views